Login to Your Account



Musical hairs: Alopecia bid Concert's next play, phase I to JAK up in second quarter

By Randy Osborne
Staff Writer

Thursday, May 5, 2016

With the FDA having specifically called out alopecia areata in its list of patient-focused drug development concerns, Concert Pharmaceuticals Inc. could be "in the right place at the right time" with new pipeline candidate CTP-543.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription